Supplement 

Phosphodiesterase Inhibitors

At this closed symposium, sponsored by Bayer and GlaxoSmithKline, various aspects of the biology and pharmacology of NO/cGMP signaling and PDE5 were discussed, with special emphasis on newer PDE5 inhibitors and potential new therapeutics focused on NO signaling, especially endothelial and neuronal NO synthases.

Editorial Commentary

Original Researches